Jazz Pharmaceuticals plc

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Jazz Pharmaceuticals plc
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Ireland
Headquarters city: Dublin
Headquarters country: Ireland
Fiscal year end: December
Ticker symbol: JAZZ
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001232524
EIN: 98-1032470
Wikidata ID: Q16255113

Board of directors

Follow this board

Anne ORiordan · Director
Since 2023
Bruce C. Cozadd · Director · Chairman & CEO
Since 2023
Catherine A. Sohn · Director
Since 2023
Heather Ann McSharry · Director
Since 2023
Jennifer E. Cook · Director
Since 2023
Kenneth W. O'Keefe · Director
Since 2023
Laura Hamill · Director
Since 2024
Mark Douglas Smith · Director
Since 2023
Norbert G. Riedel · Director
Since 2023
Patrick G. Enright · Director Overboarded
Since 2023
Patrick Kennedy · Director
Since 2024
Peter Gray · Director
Since 2023
Renee D. Gala · Director · President & CEO
Since 2026
Rick E. Winningham · Director
Since 2023
Seamus Mulligan · Director
Since 2023
Ted W. Love · Director Overboarded
Since 2025

Chief executives

Bruce C. Cozadd · Chairman & CEO

Dates unknown

Renee D. Gala · President & CEO

Dates unknown

Director election results

Annual meeting of July 23, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

8 of this board's directors also sit on 20 other boards. 19 are in the same sector.

Shared director Other board Same sector +4 more in the list below

Altimmune Inc. Same sector
via Catherine A. Sohn
AnaptysBio Inc. Same sector
via Laura Hamill
BioAge Labs Inc. Same sector
via Patrick G. Enright
BridgeBio Pharma Inc. Same sector
via Jennifer E. Cook
Denali Therapeutics Inc. Same sector
via Jennifer E. Cook
DexCom Inc. Same sector
via Renee D. Gala
Eton Pharmaceuticals Inc. Same sector
via Norbert G. Riedel
Fate Therapeutics Inc. Same sector
via Laura Hamill
Gilead Sciences Inc. Same sector
via Ted W. Love
Gossamer Bio Inc. Same sector
via Renee D. Gala
Lisata Therapeutics Inc. Same sector
via Ted W. Love
Maze Therapeutics Inc. Same sector
via Catherine A. Sohn
Phreesia Inc.
via Mark Douglas Smith
Royalty Pharma plc Same sector
via Ted W. Love
Scilex Holding Company Same sector
via Laura Hamill
Structure Therapeutics Inc. Same sector
via Ted W. Love
Teladoc Health Inc. Same sector
via Mark Douglas Smith
Vera Therapeutics Inc. Same sector
via Patrick G. Enright
Veradermics Incorporated Same sector
via Patrick G. Enright
Zenas BioPharma Inc. Same sector
via Patrick G. Enright

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $87,900,331; 67 sales by 11 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 6, 2026	Bruce C. Cozadd Director	Option exercise	+734	$136.18	$99,956
Nov 6, 2026	Bruce C. Cozadd Director	Option exercise	+85,766	$136.18	$11,679,614
Nov 6, 2026	Bruce C. Cozadd Director	Open-market sale	−27,714	$234.91	$6,510,357
Nov 6, 2026	Bruce C. Cozadd Director	Open-market sale	−10,688	$235.82	$2,520,466
Nov 6, 2026	Bruce C. Cozadd Director	Open-market sale	−24,483	$236.84	$5,798,652
Nov 6, 2026	Bruce C. Cozadd Director	Open-market sale	−5,923	$237.39	$1,406,043
Nov 4, 2026	Carr Patricia Officer (SVP, Chief Accounting Officer)	Option exercise	+1,250	$140.03	$175,038
Nov 4, 2026	Carr Patricia Officer (SVP, Chief Accounting Officer)	Open-market sale	−1,250	$231.37	$289,213
Nov 4, 2026	Carr Patricia Officer (SVP, Chief Accounting Officer)	Open-market sale	−163	$231.27	$37,697
Nov 3, 2026	Renee D. Gala Director, Officer (President & CEO)	Open-market sale	−1,000	$225.37	$225,370
Nov 2, 2026	Bruce C. Cozadd Director	Open-market sale	−6,000	$215.84	$1,295,040
Oct 6, 2026	Renee D. Gala Director, Officer (President & CEO)	Open-market sale	−2,000	$236.40	$472,800
Oct 1, 2026	Bruce C. Cozadd Director	Open-market sale	−6,000	$230.33	$1,381,980
Sep 10, 2026	Neena M. Patil Officer (EVP & Chief Legal Officer)	Open-market sale	−1,200	$240.94	$289,128
Sep 8, 2026	Renee D. Gala Officer (President & CEO)	Shares withheld for tax	−1,967	$246.81	$485,475

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

Alkermes plc Nasdaq: ALKS · Dublin 4, Ireland Organization Amarin Corporation plc Nasdaq: AMRN · Dublin 2, Ireland Organization 3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization

Questions about Jazz Pharmaceuticals plc

Who is the CEO of Jazz Pharmaceuticals plc?

Bruce C. Cozadd is Jazz Pharmaceuticals plc's Chairman & CEO.

How many directors are on Jazz Pharmaceuticals plc's board?

Jazz Pharmaceuticals plc's board has 16 directors: Anne ORiordan, Bruce C. Cozadd, Catherine A. Sohn, Heather Ann McSharry, Jennifer E. Cook, Kenneth W. O'Keefe, Laura Hamill, Mark Douglas Smith, Norbert G. Riedel, Patrick G. Enright and 6 others.

Are Jazz Pharmaceuticals plc insiders buying or selling shares?

Over the last 12 months, Jazz Pharmaceuticals plc insiders made no open-market purchases and sold $87.9 million of shares in 67 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Jazz Pharmaceuticals plc connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="jazz-pharmaceuticals-plc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.